A.A. YUDENICHEVA¹, V.I. RUZOV²

 ¹Volsk Regional Hospital, Volsk

²Ulyanovsk State University, Ulyanovsk

Contact details:

Yudenicheva A.A. — cardiologist

Address: 22 Kommunisticheskaya St., 412909 Volsk, Russian Federation, tel.: +7-902-245-41-84, e-mail: anutka-minakova@rambler.ru

 Cardiovascular diseases are known to be one of the major causes of mortality, leading to significant economic losses to society. Several risk factors associated with cardiovascular disease were identified, such as hypertension, obesity, smoking, alcohol abuse, sedentary lifestyle, dyslipidemia, hyperuricemia, impaired carbohydrate tolerance, type 2 diabetes mellitus (T2DM), metabolic syndrome (MS), etc. Metabolic syndrome is a cluster of metabolic risk factors that have been shown to double the risk of cardiovascular disease and increase the risk of all-cause mortality by 1.5 times. The review describes the role of adipokines in the diagnosis of cardiovascular diseases, as well as the metabolic mechanisms of CVD development in obesity.

Key words: adipokines, adipose tissue, obesity, resistin, vaspin.

REFERENCES

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sexspecific morta3lity for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, vol. 392 (10159), pp. 1736–1788. DOI: 10.1016/S0140-6736(18)32203-7
2. https://www.who.int/ru/health-topics/hypertension/cardiovascular-diseases#tab=tab_1
3. Khan M.A., Hashim M.J., Mustafa H. et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus, 2020, vol. 12 (7), p. e9349. DOI :10.7759/cureus.9349
4. Baza dannykh “Zdorov’e dlya vsekh” (HFA-DB) [Health for All Database (HFA-DB)], available at: https://gateway.euro.who.int/ru/datasets/european-health-for-all-database/
5. Zdravookhranenie v Rossii. 2023 Komp’yuternaya verstka Glavnogo mezhregional’nogo tsentra obrabotki i rasprostraneniya statisticheskoy informatsii Federal’noy sluzhby gosudarstvennoy statistiki, otv. za vypusk: S.N. Klimaev, V.V. Garin, I.V. Medvedeva, 2023 [Healthcare in Russia. 2023 Computer layout of the Main Interregional Center for Processing and Dissemination of Statistical Information of the Federal State Statistics Service / responsible for the release: S.N. Klimaev, V.V. Garin, I.V. Medvedeva, 2023].
6. Shepel’ R.N., Samorodskaya I.V., Kakorina E.P., Drapkina O.M. Dynamics and structure of mortality from chronic ischemic heart disease among men and women in the Russian Federation in 2014–2023. Rossiyskiy kardiologicheskiy zhurnal, 2024, vol. 29 (12S), p. 6198 (in Russ.). DOI: 10.15829/1560-4071-2024-6198
7. Samorodskaya I.V., Bubnova M.G., Akulova O.A., Drapkina O.M. Male and female mortality rates from acute forms of coronary heart disease in five-year age groups in the Russian Federation: what do the numbers say? Kardiovaskulyarnaya terapiya i profilaktika, 2022, vol. 21 (12), p. 3460 (in Russ.). DOI: 10.15829/1728-8800-2022-3460
8. Oshchepkova E.V., Efremova Yu.E., Karpov Yu.A. Morbidity and mortality from myocardial infarction in the Russian Federation in 2000–2011. Terapevticheskiy arkhiv, 2013, vol. 85, no. 4, pp. 4–10yu (in Russ.).
9. Baza dannykh Eurostat [Eurostat database], available at: https://ec.europa.eu/eurostat/web/main/data/database
10. Murataliev T.M., Zventsova V.K., Neklyudova Yu.N., Radzhapova Z.T., Mukhtarenko S.Yu. Gender features of the course of acute myocardial infarction. Klinitsist, 2016, no. 3 (in Russ.), available at: https://cyberleninka.ru/article/n/gendernye-osobennosti-techeniya-ostrogo-infarkta-miokarda (accessed on: 30.01.2025).
11. Beybalaeva A.M., Kudaev M.T., Gadzhieva T.A., Ataeva Z.N. et al. Study of the relationship between sex hormone deficiency and the occurrence of acute myocardial infarction in men and women. Sovremennye problemy nauki i obrazovaniya, 2022 (in Russ.). UDK 616.127-005.8-055:612.433.018
12. Ozhirenie i izbytochnyy ves [Obesity and overweight], available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on: 01.03.2024).
13. Boyarinova M.A., Rotar’ O.P., Konradi A.O. Adipokines and cardiometabolic syndrome. AG, 2014, no. 5 (in Russ.), available at: https://cyberleninka.ru/article/n/adipokiny-i-kardiometabo-licheskiy-sindrom
14. Vavilova T.P., Pleten’ A.P., Mikheev R.K. Biological role of adipokines and their association with morbid conditions. Vopr. Pitan, 2017, vol. 86 (2), pp. 5–13. Russian. DOI: 10.24411/0042-8833-2017-00028
15. Zhuraeva Kh.I., Kayumov L.Kh., Ubaydova D.S., Dzhabborov Zh.Zh. Relationship between myocardial infarction and metabolic syndrome. Biologiya i integrativnaya meditsina, 2019, no. 4 (32) (in Russ.), available at: https://cyberleninka.ru/article/n/vzaimosvyaz-infarkta-miokarda-s-metabolicheskim-sindromom
16. Horwich T.B., Fonarow G.C., Clark A.L. Obesity and the obesity paradox in heart failure. Prog. Cardiovasc. Dis, 2018, vol. 61 (2), pp. 151–156.
17. Borodkina D.A., Gruzdeva O.V., Kvitkova L.V., Barbarash O.L. Can visceral obesity be called a key factor in the obesity paradox? Probl. endokr., 2016, no. 6 (in Russ.), available at: https://cyberleninka.ru/article/n/mozhno-li-nazvat-vistseralnoe-ozhirenie-klyuchevym-faktorom-paradoksa-ozhireniya
18. Marinova-Zlatinova Zh., Negreva M., Chervenkov Tr. Cardiovascular diseases and adipokines: the role of visfatin in coronary atherosclerosis. Int. J. Biomed, 2024, vol. 14 (1), pp. 9–14.
19. Vorob’ev A.M. Kharakter i prediktory kardial’noy disfunktsii v postinfarktnom periode: dis. …kand. med. nauk, 2024 [The nature and predictors of cardiac dysfunction in the post-infarction period. Dis. of PhD med. sciences].
20. Dzhioeva O.N., Timofeev Yu.S., Metel’skaya V.A., Bogdanova A.A. et al. The role of epicardial adipose tissue in the pathogenesis of chronic inflammation in heart failure with preserved ejection fraction. Kardiovaskulyarnaya terapiya i profilaktika, 2024, vol. 23, no. 3, p. 3928 (in Russ.). DOI: 10.15829/1728-8800-2024-3928
21. Ismaiel A., Spinu M., Budisan L., Daniel-Corneliu L., Stefan-Lucian P., Chis B. et al. Relationship between adipokines and cardiovascular ultrasound parameters in metabolic-dysfunction-associated fatty liver disease. J. Clin. Med, 2021, no. 10, p. e. 5194.
22. Garbuzova E.V., Khudyakova A.D., Alekseev S.E. Associations of adipokines with coronary heart disease in young and middle-aged people. Ateroskleroz, 2023, vol. 19, no. 4, pp. 444–456 (in Russ.).
23. Naderian M., Kristjan Norland, Daniel J. Schaid et al. development and evaluation of a comprehensive prediction model for incident coronary heart disease using genetic, social, and lifestyle-psychological factors: a prospective analysis of the UK Biobank. Ann. Intern. Med, 2025, vol. 178 (1), pp. 1–10. DOI: 10.7326/ANNALS-24-00716
24. Van X., Chen X., Tyan’ T. et al. Sistema otsenki dlya prognozirovaniya vozniknoveniya ochen’ pozdnego tromboza stenta posle chreskozhnogo koronarnogo vmeshatel’stva pri ostrom koronarnom syndrome [A scoring system for predicting the occurrence of very late stent thrombosis after percutaneous coronary intervention for acute coronary syndrome]. Sci Rep., 10, 6378 (2020) (in Russ.). https://doi.org/10.1038/s41598-020-63455-0140
25. Wallerstedt S., Eriksson A.‐L., Niklason A., Ohlsson C., Hedner T. Serum leptin and myocardial infarction in hypertension. Blood Pres, 2004, vol. 13 (4).
26. Yang R., Barouch L.A. Leptin signaling and obesity: cardiovascular consequences. Circ. Res, 2007, vol. 101 (6), pp. 545–559. DOI: 10.1161/CIRCRESAHA.107.156596
27. Ayelign B., Akalu Y., Shibabaw T., Molla M.D. Effect of leptin on chronic complication. Diabetes Metab. Syndr. Obes. Dessie Inflammatory Disorders: Insights to Therapeutic Target to Prevent Further Cardiovascular G, 2021, no. 14, pp. 3307–3322.
28. Ghaedian M.M., Nazari Jaz A., Momeni M., Ghaedian T., Samiei N. Plasma leptin level is positively associated with blood pressure measures independent of gender and BMI. Clin. Exp. Hypertens, 2020, vol. 42 (1), pp. 31–35.
29. Pandit R., Beerens S., Adan R.A. Role of leptin in energy expenditure: the hypothalamic perspective. Am. J. Physiol, 2019, vol. 312 (6), pp. R938–R947.
30. Yue H., Zhang Q., Chang S., Zhao X., Wang M., Li W. Adiponectin protects against myocardial ischemia-reperfusion injury: a systematic review and meta-analysis of preclinical animal studies. Lipids Health Dis, 2024, vol. 23 (1), p. 51. DOI: 10.1186/s12944-024-02028-w
31. Youn B.S., Klöting N., Kratzsch J., Lee N., Park J.W., Song E.S. et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes, 2008, vol. 57 (2), pp. 372–377.
32. Avsaragova A.Z., Astakhova Z.T., Remizov O.V., Belenchekov A.A. Synergistic effect of adipokines and acute phase proteins on the risk of cardiovascular complications using the resistin-fibrinogen dyad as an example. Sovremennye problemy nauki i obrazovaniya, 2019, no. 6 (in Russ.). UDK 616-005.8-092.6:615.03
33. Lebedev P., Mateesku K., Verbovoy A., Malkova O., Aleksandrov M. Analysis of resistin, adiponectin and leptin levels in patients with acute ST-elevation myocardial infarction. Vrach, 2016, no. 3 (in Russ.), available at: https://cyberleninka.ru/article/n/analiz-soderzhaniya-rezistina-adiponektina-i-leptina-u-patsientov-s-ostrym-infarktom-miokarda-s-podemom-st
34. Stančík M., Ságová I., Kantorová E., Mokáň M. The role of vaspin as a predictor of coronary angiography result in SCAD (stable coronary artery disease) patients. BMC Cardiovasc. Disord, 2017, vol. 17 (1), p. 117. DOI: 10.1186/s12872-017-0550-1